|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB, Davila JA, Petersen NJ and
McGlynn KA: The continuing increase in the incidence of
hepatocellular carcinoma in the United States: an update. Ann
Intern Med. 139:817–823. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dawson LA, Normolle D, Balter JM, McGinn
CJ, Lawrence TS and Ten Haken RK: Analysis of radiation-induced
liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol
Phys. 53:810–821. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mornex F, Girard N, Beziat C, Kubas A,
Khodri M, Trepo C and Merle P: Feasibility and efficacy of
high-dose three-dimensional-conformal radiotherapy in cirrhotic
patients with small-size hepatocellular carcinoma non-eligible for
curative therapies - mature results of the French Phase II RTF-1
trial. Int J Radiat Oncol Biol Phys. 66:1152–1158. 2006. View Article : Google Scholar
|
|
5
|
Girard N and Mornex F: External
radiotherapy for hepatocellular carcinoma. Cancer Radiother.
15:49–53. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang SX, Zhu XD, Lu HJ, et al:
Hypofractionated three-dimensional conformal radiation therapy for
primary liver carcinoma. Cancer. 103:2181–2188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diamanti-Kandarakis E, Economou F,
Palimeri S and Christakou C: Metformin in polycystic ovary
syndrome. Ann NY Acad Sci. 1205:192–198. 2010. View Article : Google Scholar
|
|
8
|
Bianchi C, Penno G, Romero F, Del Prato S
and Miccoli R: Treating the metabolic syndrome. Expert Rev
Cardiovasc Ther. 5:491–506. 2007. View Article : Google Scholar
|
|
9
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kourelis TV and Siegel RD: Metformin and
cancer: new applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tennant DA, Durán RV and Gottlieb E:
Targeting metabolic transformation for cancer therapy. Nat Rev
Cancer. 10:267–277. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ben Sahra I, Le Marchand-Brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: a new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
|
|
13
|
Zakikhani M, Dowling RJ, Sonenberg N and
Pollak MN: The effects of adiponectin and metformin on prostate and
colon neoplasia involve activation of AMP-activated protein kinase.
Cancer Prev Res (Phila). 1:369–375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hardie DG: Adenosine
monophosphate-activated protein kinase: a central regulator of
metabolism with roles in diabetes, cancer, and viral infection.
Cold Spring Harb Symp Quant Biol. 76:155–164. 2011. View Article : Google Scholar
|
|
16
|
Buzzai M, Jones RG, Amaravadi RK, et al:
Systemic treatment with the antidiabetic drug metformin selectively
impairs p53-deficient tumor cell growth. Cancer Res. 67:6745–6752.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hou M, Venier N, Sugar L, et al:
Protective effect of metformin in CD1 mice placed on a high
carbohydrate-high fat diet. Biochem Biophys Res Commun.
397:537–542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hassan MM, Curley SA, Li D, et al:
Association of diabetes duration and diabetes treatment with the
risk of hepatocellular carcinoma. Cancer. 116:1938–1946. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lalau JD and Race JM: Lactic acidosis in
metformin therapy. Drugs. 1:55–60. 1999. View Article : Google Scholar
|
|
20
|
Vanderlinde RE: Measurement of total
lactate dehydrogenase activity. Ann Clin Lab Sci. 15:13–31.
1985.PubMed/NCBI
|
|
21
|
van Dyk E and Pretorius PJ: DNA damage and
repair in mammalian cells exposed to p-hydroxyphenylpyruvic acid.
Biochem Biophys Res Commun. 338:815–819. 2005.PubMed/NCBI
|
|
22
|
Gu YX, Fan SS, Xiong Y, et al: Cloning and
functional characterization of TCRP1, a novel gene mediating
resistance to cisplatin in an oral squamous cell carcinoma cell
line. FEBS Lett. 585:881–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ortega AD, Sánchez-Aragó M, Giner-Sánchez
D, Sánchez-Cenizo L, Willers I and Cuezva JM: Glucose avidity of
carcinomas. Cancer Lett. 276:125–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rahbari NN, Mehrabi A, Mollberg NM, Müller
SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma:
current management and perspectives for the future. Ann Surg.
253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sanli T, Rashid A, Liu C, et al: Ionizing
radiation activates AMP-activated kinase (AMPK): a target for
radiosensitization of human cancer cells. Int J Radiat Oncol Biol
Phys. 78:221–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kinner A, Wu W, Staudt C and Iliakis G:
Gamma-H2AX in recognition and signaling of DNA double-strand breaks
in the context of chromatin. Nucleic Acids Res. 36:5678–5694. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Judit PB, Susan HM and Peggy LO: Radiation
sensitivity, H2AX phosphorylation, and kinetics of repair of DNA
strand breaks in irradiated cervical cancer cell lines. Cancer Res.
64:7144–7149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Klokov D, MacPhail SM, Banáth JP, Byrne JP
and Olive PL: Phosphorylated histone H2AX in relation to cell
survival in tumor cells and xenografts exposed to single and
fractionated doses of X-rays. Radiother Oncol. 80:223–229. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Raju U, Nakata E, Yang P, Newman RA, Ang
KK and Milas L: In vitro enhancement of tumor cell radiosensitivity
by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic
considerations. Int J Radiat Oncol Biol Phys. 54:886–894. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang G, Wang H and Yang LX: Enhancement
of radiation-induced DNA damage and inhibition of its repair by a
novel camptothecin analog. Anticancer Res. 30:937–944.
2010.PubMed/NCBI
|
|
31
|
Petermann E, Ziegler M and Oei SL:
ATP-dependent selection between single nucleotide and long patch
base excision repair. DNA Repair. 2:1101–1114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lammens K, Bemeleit DJ, Mockel C, et al:
The Mre11:Rad50 structure shows an ATP-dependent molecular clamp in
DNA double-strand break repair. Cell. 145:54–66. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lyamzaev KG, Izyumov DS and Avetisyan AV:
Inhibition of mitochondrial bioenergetics: the effects on structure
of mitochondria in the cell and on apoptosis. Acta Biochim Pol.
51:553–562. 2004.PubMed/NCBI
|
|
34
|
Halicka HD, Zhao H, Li JW, Traganos1 F,
Zhang SF, Lee M and Darzynkiewicz1 Z: Genome protective effect of
metformin as revealed by reduced level of constitutive DNA damage
signaling. Aging. 3:1–11. 2011.PubMed/NCBI
|
|
35
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kisfalvi K, Eibl G, Sinnett-Smith J and
Rozengurt E: Metformin disrupts crosstalk between G protein-coupled
receptor and insulin receptor signaling systems and inhibits
pancreatic cancer growth. Cancer Res. 69:6539–6545. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ben Sahra I, Laurent K, Loubat A, et al:
The antidiabetic drug metformin exerts an antitumoral effect in
vitro and in vivo through a decrease of cyclin D1 level. Oncogene.
27:3576–3586. 2008.PubMed/NCBI
|
|
38
|
Algire C, Zakikhani M, Blouin MJ, Shuai JH
and Pollak M: Metformin attenuates the stimulatory effect of a
high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat
Cancer. 15:833–839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rattan R, Giri S, Hartmann LC and Shridhar
V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase
dispensable manner. J Cell Mol Med. 15:166–178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Scheen AJ: Clinical pharmacokinetics of
metformin. Clin Pharmacokinet. 30:359–371. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Isoda K, Young JL, Zirlik A, et al:
Metformin inhibits proinflammatory responses and nuclear
factor-kappaB in human vascular wall cells. Arterioscler Thromb
Vasc Biol. 26:611–617. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Graham GG, Punt J, Arora M, et al:
Clinical pharmacokinetics of metformin. Clin Pharmacokinet.
50:81–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
